Presentation on theme: "February 12, 2014 - USA Adis R&D Insight SLA – Pipeline Town Hall Ben Weintraub and Jeff Southwood."— Presentation transcript:
February 12, USA Adis R&D Insight SLA – Pipeline Town Hall Ben Weintraub and Jeff Southwood
WHY ADIS R&D INSIGHT February 12, USA2
Why? – Experience, Expertise, and Timeliness Editorial Staff 150+ highly qualified (PhD, MD, PharmD) staff in-house Average writing experience = 7-10 years (some up to 20 years) Expertise across extensive range of therapeutic areas Rigorous training program Global focus inThought Team 10 years experience covering pharma for Wall Street Practicing physicians on staff to provide the clinicians perspective Network of medical experts Daily updates from company contacts, press releases, international conferences, company websites, and journals February 12, USA3 Comprehensive pipeline of preclinical, clinical, and launched compounds, updated daily using sources from around the world.
Why? – Scientific/Clinical Emphasis In-depth reviews of launched products and compounds in development worldwide covering all indications, countries, and phases Concise summaries of pivotal clinical trials with links to full study profiles in Adis Clinical Trials Insight Comprehensive drug development history provides timeline for key events and milestones throughout the development process Detailed synopsis of pharmacokinetics, pharmacodynamics, and adverse events broken out by indication Global phase of development table documents progress by country/region February 12, USA4 Extensively referenced profiles provide a narrative of each drugs developmental history.
Why? – inThought Commercial Assessments inThought Approvability Index Probability of FDA approval Available for all drugs in active clinical development Based on specific factors in each phase of clinical development and benchmarked against historical parameters Absolute probability of approval as well as comparison to similar agents Revenue Forecasts Models assess both currently approved and developmental drugs Top-down, based on the addressable patient population Forecasts seven years in the future and three years in the past Models incorporate Wolters Kluwers Healthcare Analytics prescription data February 12, USA5 Single-source estimates provide a consistent view of FDA approvability and worldwide revenue potential.
Why? – Ease of Use Intuitive search by name, class, mechanism, organization, development role, indication, patient segment, phase, and country Refine search results to include drugs that are only available for licensing, small molecules, fixed combinations, orphan drugs, fast track status, biological, in active development Save searches, send searches, revise searches Alerts based on saved searches February 12, USA6 Gilead Products by Phase 17 Launched 10 Phase II 28 Discontinued - Preclinical 12 No Develop- ment Reported
Why? – Workflow Solution Tools Create Excel and PowerPoint tables and graphs from search results Export to Excel or HTML Exported charts have links to the database that do not require a password – to anyone February 12, USA7
Why? – Customer Support Ask-The-Expert service provides complimentary access to our team of scientific experts, financial analysts, and physician consultants to help answer your specific questions February 12, USA8
EMERGING TRENDS February 12, USA9
Emerging Trends Pharma is increasing the pace and sophistication of licensing and acquisitions, driving a need for better information to screen candidates and more diverse and detailed information about each product Emerging markets: visibility into India, China, and other emerging markets are becoming critical Pharma doesnt want a data dump…they need a strategic partner who can synthesize, condense, and summarize all the available information in a meaningful way that provides insights that are commercially relevant to their specific business and business issues Mix of secondary and primary information, mix of facts and opinions February 12, USA10 Drug database users want a single source for clinical data summaries, forecasts, commercial information, and business development solutions.
FUTURE DEVELOPMENTS February 12, USA11
Future Development Single site source for clinical, commercial, deals, and regulatory Incorporate other content from within Wolters Kluwer Sales and managed care content from Source Healthcare Analytics Clinical Trial content from Adis Clinical Trials Insight Epidemiology and clinical content from UpToDate inThought Research alert content Partner with 3 rd parties for additional commercial content Consensus revenue estimates Consensus launch dates Patent expiry February 12, USA12 Building a single source for clinical data summaries, forecasts, commercial information, and business development solutions.